APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV Prevention Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global HIV Prevention Drug Industry Growth and Trends Forecast to 2032

28 December 202576 pages

Choose your research edition.

Industry ResearchHIV Prevention Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Prevention Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal HIV Prevention Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Prevention Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Prevention Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global HIV Prevention Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV Prevention Drug include Gilead Sciences and ViiV Healthcare among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global HIV Prevention Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The HIV Prevention Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global HIV Prevention Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to HIV Prevention Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global HIV Prevention Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

HIV Prevention Drug Market by Company

Gilead Sciences

ViiV Healthcare

HIV Prevention Drug Segment by Type

Lenacapavir

Cabotegravir

HIV Prevention Drug Segment by Application

Hospital

Clinic

Others

HIV Prevention Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Prevention Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Prevention Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Prevention Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Prevention Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of HIV Prevention Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Lenacapavir Table 2. Major Company of Cabotegravir Table 3. Global HIV Prevention Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 5. Global HIV Prevention Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global HIV Prevention Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global HIV Prevention Drug Price by Type (2021-2026) & (US$/Unit) Table 9. Global HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 10. Global HIV Prevention Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global HIV Prevention Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global HIV Prevention Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global HIV Prevention Drug Price by Type (2027-2032) & (US$/Unit) Table 14. North America HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 15. North America HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 17. Europe HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 21. Latin America HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa HIV Prevention Drug Sales by Type (2021-2026) & (US$ Million) Table 24. HIV Prevention Drug Industry Trends Table 25. HIV Prevention Drug Industry Drivers Table 26. HIV Prevention Drug Industry Opportunities and Challenges Table 27. HIV Prevention Drug Industry Restraints Table 28. Global HIV Prevention Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global HIV Prevention Drug Revenue Market Share by Company (2021-2026) Table 30. Global HIV Prevention Drug Sales by Company (2021-2026) & (K Units) Table 31. Global HIV Prevention Drug Sales Share by Company (2021-2026) Table 32. Global HIV Prevention Drug Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global HIV Prevention Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global HIV Prevention Drug Major Company Production Sites and Headquarters Table 35. Global HIV Prevention Drug Company, Product Type & Application Table 36. Global HIV Prevention Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global HIV Prevention Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global HIV Prevention Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global HIV Prevention Drug Sales by Region (2021-2026) & (K Units) Table 41. Global HIV Prevention Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global HIV Prevention Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global HIV Prevention Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global HIV Prevention Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global HIV Prevention Drug Sales by Region (2027-2032) & (K Units) Table 46. Global HIV Prevention Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global HIV Prevention Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global HIV Prevention Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global HIV Prevention Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global HIV Prevention Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 52. Global HIV Prevention Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global HIV Prevention Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global HIV Prevention Drug Price by Application (2021-2026) & (US$/Unit) Table 56. Global HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 57. Global HIV Prevention Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global HIV Prevention Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global HIV Prevention Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global HIV Prevention Drug Price by Application (2027-2032) & (US$/Unit) Table 61. North America HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 62. North America HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 64. Europe HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 68. Latin America HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa HIV Prevention Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Gilead Sciences Company Information Table 72. Gilead Sciences Business Overview Table 73. Gilead Sciences HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Gilead Sciences HIV Prevention Drug Product Portfolio Table 75. Gilead Sciences Recent Development Table 76. ViiV Healthcare Company Information Table 77. ViiV Healthcare Business Overview Table 78. ViiV Healthcare HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. ViiV Healthcare HIV Prevention Drug Product Portfolio Table 80. ViiV Healthcare Recent Development Table 81. North America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 82. North America HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 83. North America HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 84. North America HIV Prevention Drug Sales Forecast by Country (2027-2032) & (K Units) Table 85. North America HIV Prevention Drug Sales Market Share Forecast by Country (2027-2032) Table 86. North America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 87. North America HIV Prevention Drug Market Size by Country (2021-2026) & (US$ Million) Table 88. North America HIV Prevention Drug Market Share by Country (2021-2026) Table 89. North America HIV Prevention Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 90. North America HIV Prevention Drug Market Share Forecast by Country (2027-2032) Table 91. Europe HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 92. Europe HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 93. Europe HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 94. Europe HIV Prevention Drug Sales Forecast by Country (2027-2032) & (K Units) Table 95. Europe HIV Prevention Drug Sales Market Share Forecast by Country (2027-2032) Table 96. Europe HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 97. Europe HIV Prevention Drug Market Size by Country (2021-2026) & (US$ Million) Table 98. Europe HIV Prevention Drug Market Share by Country (2021-2026) Table 99. Europe HIV Prevention Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 100. Europe HIV Prevention Drug Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 103. Asia-Pacific HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 104. Asia-Pacific HIV Prevention Drug Sales Forecast by Country (2027-2032) & (K Units) Table 105. Asia-Pacific HIV Prevention Drug Sales Market Share Forecast by Country (2027-2032) Table 106. Asia-Pacific HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. Asia-Pacific HIV Prevention Drug Market Size by Country (2021-2026) & (US$ Million) Table 108. Asia-Pacific HIV Prevention Drug Market Share by Country (2021-2026) Table 109. Asia-Pacific HIV Prevention Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. Asia-Pacific HIV Prevention Drug Market Share Forecast by Country (2027-2032) Table 111. Latin America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Latin America HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 113. Latin America HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 114. Latin America HIV Prevention Drug Sales Forecast by Country (2027-2032) & (K Units) Table 115. Latin America HIV Prevention Drug Sales Market Share Forecast by Country (2027-2032) Table 116. Latin America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Latin America HIV Prevention Drug Market Size by Country (2021-2026) & (US$ Million) Table 118. Latin America HIV Prevention Drug Market Share by Country (2021-2026) Table 119. Latin America HIV Prevention Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Latin America HIV Prevention Drug Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 123. Middle East and Africa HIV Prevention Drug Sales Market Share by Country (2021-2026) Table 124. Middle East and Africa HIV Prevention Drug Sales Forecast by Country (2027-2032) & (K Units) Table 125. Middle East and Africa HIV Prevention Drug Sales Market Share Forecast by Country (2027-2032) Table 126. Middle East and Africa HIV Prevention Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Middle East and Africa HIV Prevention Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. Middle East and Africa HIV Prevention Drug Market Share by Country (2021-2026) Table 129. Middle East and Africa HIV Prevention Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Middle East and Africa HIV Prevention Drug Market Share Forecast by Country (2027-2032) Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. HIV Prevention Drug Distributors List Table 134. HIV Prevention Drug Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. HIV Prevention Drug Image Figure 2. Global HIV Prevention Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Prevention Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Prevention Drug Sales (2021-2032) & (K Units) Figure 5. Lenacapavir Image Figure 6. Global Lenacapavir Sales YoY Growth (2021-2032) & (K Units) Figure 7. Cabotegravir Image Figure 8. Global Cabotegravir Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global HIV Prevention Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global HIV Prevention Drug Market Share by Type 2025 VS 2032 Figure 11. North America HIV Prevention Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America HIV Prevention Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe HIV Prevention Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe HIV Prevention Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific HIV Prevention Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific HIV Prevention Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America HIV Prevention Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America HIV Prevention Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa HIV Prevention Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa HIV Prevention Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 HIV Prevention Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global HIV Prevention Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global HIV Prevention Drug Market Share by Application 2025 VS 2032 Figure 31. North America HIV Prevention Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America HIV Prevention Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe HIV Prevention Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe HIV Prevention Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific HIV Prevention Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific HIV Prevention Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America HIV Prevention Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America HIV Prevention Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa HIV Prevention Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa HIV Prevention Drug Sales Market Share in Value by Application in 2025 Figure 41. North America HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America HIV Prevention Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America HIV Prevention Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America HIV Prevention Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe HIV Prevention Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe HIV Prevention Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe HIV Prevention Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific HIV Prevention Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific HIV Prevention Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific HIV Prevention Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America HIV Prevention Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America HIV Prevention Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America HIV Prevention Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa HIV Prevention Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa HIV Prevention Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa HIV Prevention Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa HIV Prevention Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. HIV Prevention Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. HIV Prevention Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Lenacapavir
  • Cabotegravir
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Gilead Sciences
  • ViiV Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV Prevention Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global HIV Prevention Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 HIV Prevention Drug Market by Type
  6. 1.3.1 Lenacapavir
  7. 1.3.2 Cabotegravir
  8. 1.4 Global HIV Prevention Drug Market Size by Type
  9. 1.4.1 Global HIV Prevention Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global HIV Prevention Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global HIV Prevention Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America HIV Prevention Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe HIV Prevention Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific HIV Prevention Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America HIV Prevention Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa HIV Prevention Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 HIV Prevention Drug Industry Trends
  2. 2.2 HIV Prevention Drug Industry Drivers
  3. 2.3 HIV Prevention Drug Industry Opportunities and Challenges
  4. 2.4 HIV Prevention Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by HIV Prevention Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by HIV Prevention Drug Sales (2021-2026)
  3. 3.3 Global Top Players by HIV Prevention Drug Price (2021-2026)
  4. 3.4 Global HIV Prevention Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV Prevention Drug Major Company Production Sites & Headquarters
  6. 3.6 Global HIV Prevention Drug Company, Product Type & Application
  7. 3.7 Global HIV Prevention Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV Prevention Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV Prevention Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV Prevention Drug Tier 1, Tier 2, and Tier 3
4 HIV Prevention Drug Regional Status and Outlook
  1. 4.1 Global HIV Prevention Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global HIV Prevention Drug Historic Market Size by Region
  3. 4.2.1 Global HIV Prevention Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global HIV Prevention Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global HIV Prevention Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global HIV Prevention Drug Forecasted Market Size by Region
  7. 4.3.1 Global HIV Prevention Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global HIV Prevention Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global HIV Prevention Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 HIV Prevention Drug by Application
  1. 5.1 HIV Prevention Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global HIV Prevention Drug Market Size by Application
  6. 5.2.1 Global HIV Prevention Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global HIV Prevention Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global HIV Prevention Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America HIV Prevention Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe HIV Prevention Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific HIV Prevention Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America HIV Prevention Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa HIV Prevention Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Gilead Sciences
  2. 6.1.1 Gilead Sciences Company Information
  3. 6.1.2 Gilead Sciences Business Overview
  4. 6.1.3 Gilead Sciences HIV Prevention Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
  6. 6.1.5 Gilead Sciences Recent Developments
  7. 6.2 ViiV Healthcare
  8. 6.2.1 ViiV Healthcare Company Information
  9. 6.2.2 ViiV Healthcare Business Overview
  10. 6.2.3 ViiV Healthcare HIV Prevention Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
  12. 6.2.5 ViiV Healthcare Recent Developments
7 North America by Country
  1. 7.1 North America HIV Prevention Drug Sales by Country
  2. 7.1.1 North America HIV Prevention Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America HIV Prevention Drug Sales by Country (2021-2026)
  4. 7.1.3 North America HIV Prevention Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America HIV Prevention Drug Market Size by Country
  6. 7.2.1 North America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America HIV Prevention Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America HIV Prevention Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe HIV Prevention Drug Sales by Country
  2. 8.1.1 Europe HIV Prevention Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe HIV Prevention Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe HIV Prevention Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe HIV Prevention Drug Market Size by Country
  6. 8.2.1 Europe HIV Prevention Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe HIV Prevention Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe HIV Prevention Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific HIV Prevention Drug Sales by Country
  2. 9.1.1 Asia-Pacific HIV Prevention Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific HIV Prevention Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific HIV Prevention Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific HIV Prevention Drug Market Size by Country
  6. 9.2.1 Asia-Pacific HIV Prevention Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific HIV Prevention Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific HIV Prevention Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America HIV Prevention Drug Sales by Country
  2. 10.1.1 South America HIV Prevention Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America HIV Prevention Drug Sales by Country (2021-2026)
  4. 10.1.3 South America HIV Prevention Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America HIV Prevention Drug Market Size by Country
  6. 10.2.1 South America HIV Prevention Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America HIV Prevention Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America HIV Prevention Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa HIV Prevention Drug Sales by Country
  2. 11.1.1 Middle East and Africa HIV Prevention Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa HIV Prevention Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa HIV Prevention Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa HIV Prevention Drug Market Size by Country
  6. 11.2.1 Middle East and Africa HIV Prevention Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa HIV Prevention Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa HIV Prevention Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 HIV Prevention Drug Value Chain Analysis
  2. 12.1.1 HIV Prevention Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 HIV Prevention Drug Production Mode & Process
  7. 12.2 HIV Prevention Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 HIV Prevention Drug Distributors
  10. 12.2.3 HIV Prevention Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst